Clinical Commander

Back to dossier
uro.uti.complicated.v1PRODUCTION
uro.uti.complicated.v1

Complicated UTI (men, pregnant, catheter, anatomic, IC, ESBL/MDR, fungal, prostatitis overlay)

urologyacuteadultpregnancygeriatric
Hard-required inputs
0 / 19
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

UTI symptoms + ≥1 complicating factor (man, pregnant, catheter, IC, anatomic, recurrent, ESBL/MDR, IC, candiduria, prostatitis) → complicated UTI pathway. Pivot: fever + flank pain → uro.pyelonephritis.v1; none of complicating factors → uro.uti.uncomplicated.v1 (IDSA 2010)

Inputs
3
Actions
0
Advance rule
Set
Advance when

engine scope confirmed

Patient inputs (23)

Geriatric (≥65) → atypical presentation (altered mental status), dose adjustments; pediatric routes off engine (AAP)

SOT, hematologic malignancy, HIV with low CD4, chronic steroid → broader empirics; ID consult (IDSA 2010)

Poorly controlled DM → emphysematous pyelo risk; culture; longer duration (EAU 2020)

Stricture, neurogenic bladder, reflux, calculi → workup + urology referral (AUA 2016)

Recurrent breakthrough on prophylaxis → urology referral + switch prophylaxis (AUA 2022)

Recent FQ → avoid empiric FQ; recent broad → ESBL / Pseudomonas concern (Tamma 2019)

Prior ESBL → empiric ertapenem; prior CRE → ID consult (Tamma 2019)

Men with UTI = always complicated; workup obstruction + DRE; FQ × 7–14 d or TMP-SMX (IDSA 2010)

Pregnancy + UTI / ASB → cephalosporin × 7 d; AVOID FQ throughout; admit if pyelo or sepsis (USPSTF 2019; IDSA 2010)

CAUTI pathway — remove catheter when possible; treat ONLY if symptomatic; replace before culture if retained (IDSA 2019)

Leuk-esterase + nitrite confirm; sterile pyuria → STI / TB / candiduria pivot (IDSA 2010)

ALWAYS in complicated UTI before abx (IDSA 2010)

Leukocytosis → severity; thrombocytopenia → sepsis (SCC 2026)

AKI staging + dose adjustment (KDIGO AKI 2026)

Reproductive-age women — drives regimen (USPSTF 2019)

Fever + flank pain → pyelo pathway (route off engine to uro.pyelonephritis.v1)

Flank pain → pyelo pathway (IDSA 2010)

Hypotension + fever → urosepsis ICU (SCC 2026)

Anticoagulant + sulfa INR; methotrexate + sulfa toxicity; FQ + steroid → tendinopathy (FDA)

Young sexually active man + dysuria → NAAT chlamydia + gonorrhea + trichomonas (CDC 2021)

Renal transplant or other SOT → ID + transplant team co-management (IDSA)

Sexually active man <35 + dysuria → STI panel (CDC 2021)

Renal US if obstruction / stone / anatomic concern (AUA 2016; EAU 2020)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (10)

10 need judgement
  • informationalsevereimmunocompromised_uti
    SOT, hematologic malignancy, HIV with low CD4, chronic high-dose steroid — broader empirics + ID consult low threshold (IDSA 2010)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereesbl_or_mdr_uti
    Prior ESBL E. coli / Klebsiella culture OR current ESBL OR CRE → tailored per culture; ertapenem first for ESBL; ID consult for CRE (Tamma IDSA 2020 PMID 33106864)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatemen_with_uti
    Adult man with UTI — ALWAYS complicated; workup for obstruction + DRE + prostatitis pivot (IDSA 2010 Gupta PMID 21292654)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatepregnant_uti
    Pregnant patient with UTI or ASB — treat even ASB; cephalosporin first-line; AVOID FQ throughout (cartilage); fetal monitoring (USPSTF 2019; IDSA 2010)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatecauti
    Catheter-associated UTI with symptoms (fever, suprapubic, CVA tenderness, dysuria after catheter removal, new altered mental status) — remove catheter when possible; do NOT treat ASB (IDSA 2019 PMID 20175247)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatediabetic_uti
    Poorly controlled DM with UTI — emphysematous pyelo risk; culture; longer duration (EAU 2020)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateanatomic_abnormality_uti
    Stricture, neurogenic bladder, vesicoureteral reflux, calculi → complicated UTI pathway (AUA 2016)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderaterecurrent_breakthrough
    Recurrent UTI breakthrough despite prophylaxis → urology referral + switch prophylaxis (AUA 2022)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateprostatitis_overlay
    Man with UTI + prostate tenderness on DRE OR perineal pain OR culture-confirmed prostatitis — 4–6 wk acute / 6–12 wk chronic (IDSA 2010)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildcandiduria
    Yeast in urine — treat ONLY if symptomatic OR immunocompromised OR pre-urologic procedure with mucosal trauma; otherwise DO NOT treat (IDSA candiduria 2009)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

This dossier does not reference any calculators.

Recommended regimen

Complicated UTI — empiric outpatient cephalosporin + men FQ + pregnancy cephalosporin + ESBL ertapenem + candiduria fluconazole + prostatitis 4–6 wk FQ
axis: complicated_uti_empiric_and_targetedstep 1 - Empiric outpatient (PO-tolerant, low-risk complicated) (IDSA 2010 + updates)
Selected step "Empiric outpatient (PO-tolerant, low-risk complicated) (IDSA 2010 + updates)" — Adult with complicated UTI factor, PO-tolerant, no severe sepsis, no pyelo, no anatomic emergency
  • cefpodoxime
    first line
    cephalosporin_3rd_gen
    100 mg PO BID • PO • BID × 7–14 days
    triggers: complicated_uti_PO_eligible, pregnancy_friendly
    IDSA 2010 first-line PO cephalosporin for complicated UTI; pregnancy-friendly (Gupta PMID 21292654)
    rxcui 20489
  • cefdinir
    first line
    cephalosporin_3rd_gen
    300 mg PO BID • PO • BID × 7–14 days
    triggers: cefpodoxime_alternative
    PO cephalosporin alternative; warn about red-stool with iron-fortified foods
    rxcui 25037
  • cephalexin
    first line
    cephalosporin_1st_gen
    500 mg PO QID • PO • QID × 7–14 days
    triggers: cefpodoxime_alternative, pregnancy_friendly, gram_positive_concern
    Pregnancy-safe; Staphylococcus saprophyticus coverage; QID dosing burden
    rxcui 2231

outpatient playbook — drug actions (6)

  1. 1. cefpodoxime
    100 mg PO BID × 7–14 d • PO • BID
    trigger: Complicated UTI, PO-tolerant, low-risk
    IDSA 2010 first-line PO cephalosporin (Gupta)
  2. 2. cefdinir
    300 mg PO BID × 7–14 d • PO • BID
    trigger: cefpodoxime alternative
    PO alternative; red-stool warning
  3. 3. cephalexin
    500 mg PO QID × 7–14 d • PO • QID
    trigger: Pregnancy-safe alternative; Staph saprophyticus concern
    Pregnancy-friendly; QID burden
  4. 4. ciprofloxacin (men)
    500 mg PO BID × 7–14 d • PO • BID
    trigger: Men with UTI — always complicated
    IDSA 2010 first-line for men; FDA Black Box counsel
  5. 5. TMP-SMX (alternative)
    160/800 mg PO BID × 7–14 d (men); 7 d (pregnancy avoid near term) • PO • BID
    trigger: FQ contraindicated; susceptible per culture
    IDSA 2010 alternative
  6. 6. fluconazole (candiduria)
    200–400 mg PO daily × 14 d • PO • once daily
    trigger: Symptomatic candiduria OR IC OR pre-procedure
    IDSA candiduria 2009 — only if indicated; do NOT treat asymptomatic

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Dysuria / frequency / urgency + complicating factor (man, pregnant, catheter, IC, anatomic anomaly) (IDSA 2010 Gupta PMID 21292654); Adult male with UTI — always complicated (IDSA 2010); Pregnancy + UTI or ASB — treat (USPSTF 2019).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Complicated UTI (men, pregnant, catheter, anatomic, IC, ESBL/MDR, fungal, prostatitis overlay)** (uro.uti.complicated.v1).
Phenotype framing: Complicated UTI vs prostatitis (men) vs pyelo vs CAUTI vs candiduria vs STI urethritis vs interstitial cystitis vs anatomic obstruction (IDSA 2010)
Scope: UTI symptoms + ≥1 complicating factor (man, pregnant, catheter, IC, anatomic, recurrent, ESBL/MDR, IC, candiduria, prostatitis) → complicated UTI pathway. Pivot: fever + flank pain → uro.pyelonephritis.v1; none of complicating factors → uro.uti.uncomplicated.v1 (IDSA 2010)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Complicated UTI — empiric outpatient cephalosporin + men FQ + pregnancy cephalosporin + ESBL ertapenem + candiduria fluconazole + prostatitis 4–6 wk FQ** — step "Empiric outpatient (PO-tolerant, low-risk complicated) (IDSA 2010 + updates)".
1. cefpodoxime 100 mg PO BID PO BID × 7–14 days (cephalosporin_3rd_gen, first line) — IDSA 2010 first-line PO cephalosporin for complicated UTI; pregnancy-friendly (Gupta PMID 21292654)
2. cefdinir 300 mg PO BID PO BID × 7–14 days (cephalosporin_3rd_gen, first line) — PO cephalosporin alternative; warn about red-stool with iron-fortified foods
3. cephalexin 500 mg PO QID PO QID × 7–14 days (cephalosporin_1st_gen, first line) — Pregnancy-safe; Staphylococcus saprophyticus coverage; QID dosing burden

Setting playbook (outpatient) — Stable, PO-tolerant, low-risk complicated → oral cephalosporin × 7–14 d; men FQ × 7–14 d + obstruction workup + DRE; pregnancy cephalosporin × 7 d + OB co-management; recurrent → prophylaxis + urology referral. ALWAYS obtain culture (IDSA 2010)
4. cefpodoxime 100 mg PO BID × 7–14 d PO BID — Complicated UTI, PO-tolerant, low-risk (IDSA 2010 first-line PO cephalosporin (Gupta))
5. cefdinir 300 mg PO BID × 7–14 d PO BID — cefpodoxime alternative (PO alternative; red-stool warning)
6. cephalexin 500 mg PO QID × 7–14 d PO QID — Pregnancy-safe alternative; Staph saprophyticus concern (Pregnancy-friendly; QID burden)
7. ciprofloxacin (men) 500 mg PO BID × 7–14 d PO BID — Men with UTI — always complicated (IDSA 2010 first-line for men; FDA Black Box counsel)
8. TMP-SMX (alternative) 160/800 mg PO BID × 7–14 d (men); 7 d (pregnancy avoid near term) PO BID — FQ contraindicated; susceptible per culture (IDSA 2010 alternative)
9. fluconazole (candiduria) 200–400 mg PO daily × 14 d PO once daily — Symptomatic candiduria OR IC OR pre-procedure (IDSA candiduria 2009 — only if indicated; do NOT treat asymptomatic)

Non-pharmacologic actions:
- Patient education — symptom trajectory + return precautions (worsening, fever, flank pain, no improvement at 48–72 h)
- 48–72 h follow-up call; culture results at 24–48 h → narrow / broaden per susceptibility
- Men: DRE + workup for obstruction; prostatitis 4–6 wk course if positive
- Pregnancy: OB co-management; repeat culture at 1–2 wk
- Recurrent: urology referral + prophylaxis options (AUA 2022)
- CAUTI: remove catheter when possible; replace before culture if retained

AVOID / contraindication checks:
- Asymptomatic_bacteriuria_DO_NOT_TREAT_except_pregnancy_or_pre_procedure (USPSTF / IDSA 2019)
- CAUTI_remove_catheter_when_possible_before_treating (IDSA 2019 PMID 20175247)
- CAUTI_do_NOT_treat_ASB_in_catheterized_patients (IDSA 2019)
- Fluoroquinolones_FDA_black_box_tendinopathy_aortic_CNS_dysglycemia (FDA 2016)
- Fluoroquinolones_avoid_throughout_pregnancy_cartilage (FDA / IDSA)
- Fluoroquinolones_steroid_combination_tendinopathy_amplified (FDA)
- Fluoroquinolones_prolonged_course_for_prostatitis_increases_adverse_event_risk (IDSA 2010)
- TMP_SMX_avoid_near_term_pregnancy_kernicterus (USPSTF)
- TMP_SMX_interaction_with_warfarin_INR_rise (IDSA 2010)
- TMP_SMX_interaction_with_methotrexate_toxicity (IDSA 2010)
- Nitrofurantoin_avoid_in_men_with_UTI_inadequate_for_complicated (IDSA 2010)
- Nitrofurantoin_avoid_if_CrCl_lt_30 (IDSA 2010)
- Nitrofurantoin_avoid_in_pyelonephritis_no_renal_tissue_penetration (IDSA 2010)
- Fluconazole_hepatotoxicity_QTc_drug_interactions (FDA)
- Fluconazole_avoid_asymptomatic_candiduria_drives_resistance (IDSA candiduria 2009)
- Amphotericin_B_systemic_nephrotoxicity_use_bladder_irrigation_only_for_localized (IDSA)
- Carbapenem_CNS_lowered_seizure_threshold_renal_dose_adjust (FDA)
- Cefdinir_red_stool_with_iron_fortified_food_benign (FDA)
- ESBL_use_ertapenem_first_meropenem_sparing (Tamma 2019/2020)
- CRE_MDR_ID_consult_mandatory_tailored_per_susceptibility (Tamma 2020)
- Prostatitis_FQ_or_TMP_SMX_only_due_to_prostate_penetration_requirement (IDSA 2010)

Monitoring

Regimen monitoring:
- symptom resolution by 48 to 72h (IDSA 2010)
- urine culture results at 24 to 48h adjust per susceptibility (IDSA 2010)
- reassess for pyelonephritis if fever or flank pain develops (IDSA 2010)
- pregnancy repeat culture at 1 to 2wk to confirm clearance (USPSTF 2019)
- CAUTI recheck after catheter removal or replacement (IDSA 2019)
- prostatitis prolonged FQ monitor tendinopathy CNS dysglycemia (FDA)
- fluconazole monitor LFTs and QTc during extended courses (FDA)
- recurrent breakthrough urology referral for anatomic workup (AUA 2022)
- ESBL complete culture directed course no early stop (Tamma 2019)

Setting (outpatient) monitoring:
- Symptom resolution at 48–72 h (IDSA 2010)
- Culture results at 24–48 h (IDSA 2010)
- Treatment failure → admit + IV ceftriaxone
- Prostatitis prolonged FQ → monitor tendinopathy / dysglycemia (FDA)

Follow-up plan: Urology if anatomic / recurrent / men; prophylaxis discussion if recurrent; counsel prostatitis recurrence in men; remove catheter when possible (AUA 2022; IDSA 2019)
- Close-out criterion: follow-up scheduled

Monitoring phase: Symptom resolution at 48–72 h; culture follow-up; pregnancy → repeat culture at 1–2 wk; recurrent → urology workup (IDSA 2010; AUA 2022)

Disposition

Current setting: outpatient — Stable, PO-tolerant, low-risk complicated → oral cephalosporin × 7–14 d; men FQ × 7–14 d + obstruction workup + DRE; pregnancy cephalosporin × 7 d + OB co-management; recurrent → prophylaxis + urology referral. ALWAYS obtain culture (IDSA 2010)

Disposition criteria:
- Discharge with oral abx + 48–72 h follow-up + return precautions (IDSA 2010)
- Admit if pregnancy + pyelo / sepsis / obstruction / non-PO / IC severe (IDSA 2010)

Escalation triggers (move to higher acuity):
- Treatment failure at 48–72 h → admit (IDSA 2010)
- Fever / flank pain → ED pyelo pathway (IDSA 2010)
- Sepsis screen positive → ED (SCC 2026)
- Recurrent breakthrough on prophylaxis → urology (AUA 2022)
- Pregnancy + worsening → OB + admit (USPSTF 2019)

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [SEVERE] SOT, hematologic malignancy, HIV with low CD4, chronic high-dose steroid — broader empirics + ID consult low threshold (IDSA 2010)
- [SEVERE] Prior ESBL E. coli / Klebsiella culture OR current ESBL OR CRE → tailored per culture; ertapenem first for ESBL; ID consult for CRE (Tamma IDSA 2020 PMID 33106864)
- [MODERATE] Adult man with UTI — ALWAYS complicated; workup for obstruction + DRE + prostatitis pivot (IDSA 2010 Gupta PMID 21292654)

Citations

- IDSA 2011 Acute Uncomplicated Cystitis/Pyelonephritis (Gupta) + IDSA 2010 CAUTI (Hooton) + IDSA Asymptomatic Bacteriuria 2019 (Nicolle) + IDSA 2020 MDR-GNB ESBL/CRE (Tamma) + IDSA Candidiasis 2016 (Pappas — candiduria) + Hooton NEJM 2012 UTI review [PMID:21292654](https://pubmed.ncbi.nlm.nih.gov/21292654/)
- Cited evidence (PMID 20175247) [PMID:20175247](https://pubmed.ncbi.nlm.nih.gov/20175247/)
- Cited evidence (PMID 30895288) [PMID:30895288](https://pubmed.ncbi.nlm.nih.gov/30895288/)
- Cited evidence (PMID 33106864) [PMID:33106864](https://pubmed.ncbi.nlm.nih.gov/33106864/)
- Cited evidence (PMID 26679628) [PMID:26679628](https://pubmed.ncbi.nlm.nih.gov/26679628/)

Last reconciled with current guidelines: 2026-05-22.
References
  • IDSA 2011 Acute Uncomplicated Cystitis/Pyelonephritis (Gupta) + IDSA 2010 CAUTI (Hooton) + IDSA Asymptomatic Bacteriuria 2019 (Nicolle) + IDSA 2020 MDR-GNB ESBL/CRE (Tamma) + IDSA Candidiasis 2016 (Pappas — candiduria) + Hooton NEJM 2012 UTI review — PMID:21292654
  • Cited evidence (PMID 20175247) — PMID:20175247
  • Cited evidence (PMID 30895288) — PMID:30895288
  • Cited evidence (PMID 33106864) — PMID:33106864
  • Cited evidence (PMID 26679628) — PMID:26679628